Panitumumab

From Wikipedia, the free encyclopedia

Panitumumab
Therapeutic monoclonal antibody
Source	Human
Target	?
Identifiers
CAS number	?
ATC code	L01XC08
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	∼7.5 days (range: 4-11 days)
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	intravenous

Panitumumab (ABX-EGF) is a fully human monoclonal antibody targeting the EGF receptor. It received its first licence for clinical use on humans by the FDA, for patients suffering with non-curable colorectal cancer in September 2006. ^[1] Panitumumab is manufactured by Amgen and marketed as Vectibix in the USA.

The compound works by inhibiting the activation of the EGFR (epidermal growth factor receptor). This results in a halting of a cascade of intracellular signals which would otherwise promote the cell (and cancer cells) to multiply. ^[2]

As this is a fully human monoclonal antibody, patients run less of a risk of suffering an allergic reaction during its administration (which is via the intravenous route). This is an issue that had caused problems in the use of cetuximab (Erbitux) a drug that has the same mechanism of action but it is an IgG1 chimeric monoclonal antibody. ^[3]

Panitumumab is a monoclonal antibody of the IgG2 isotype. It is produced by immunization of transgenic mice, that are able to produce human immunoglobulin light and heavy chains. After immunization a specific clone of B cells that produce an antibody against EGFR was selected and immortalized for the generation of the antibody.

[edit] References

^ U. S. Food and Drug Administration [1]
^ Plunkett, Jack W. (September 30, 2005). Plunkett's Biotech & Genetics Industry Almanac 2006 (in English). Plunkett Research, Ltd.. Retrieved on October 20, 2006.
^ (September 1, 2006) Les Cancers Digestifs (in French). Springer. Retrieved on October 20, 2006.

v • d • e Chemotherapeutic agents/Antineoplastic agents (L01)
Alkylating agents	Nitrogen mustards: (Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan). Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin). Platinum: (Carboplatin, Cisplatin, Oxaliplatin, BBR3464). Busulfan, Dacarbazine, Mechlorethamine, Procarbazine, Temozolomide, ThioTEPA, Uramustine
Antimetabolites	Folic acid: (Aminopterin, Methotrexate, Pemetrexed, Raltitrexed). Purine:(Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine). Pyrimidine:(Capecitabine, Cytarabine, Fluorouracil, Floxuridine, Gemcitabine)
Spindle poison plant alkaloids	Taxane: (Docetaxel, Paclitaxel). Vinca: (Vinblastine, Vincristine, Vindesine, Vinorelbine).
Cytotoxic/antitumor antibiotics	Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Valrubicin). Bleomycin, Hydroxyurea, Mitomycin, Actinomycin
Topoisomerase inhibitors	Camptotheca: (Camptothecin, Topotecan, Irinotecan), Podophyllum:(Etoposide, Teniposide).
CI monoclonal antibodies	Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab, Panitumumab, Rituximab, Tositumomab, Trastuzumab
Photosensitizers	Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin
Kinase inhibitors	Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Sorafenib, Sunitinib, Vandetanib (ZD6474)
Other	Alitretinoin, Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase, Bexarotene, Bortezomib, Denileukin diftitox, Estramustine, Hydroxycarbamide, Masoprocol, Mitotane, Pegaspargase, Tretinoin